# Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

> **NCT00210379** · PHASE2 · COMPLETED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 64 (actual)

## Conditions studied

- Lymphoma, B Cell

## Interventions

- **DRUG:** rituximab
- **DRUG:** CHOP
- **DRUG:** intrathecal methotrexate
- **PROCEDURE:** radiotherapy

## Key facts

- **NCT ID:** NCT00210379
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2004-11
- **Final completion:** 2007-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2009-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210379, "Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00210379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*